Log in

Relevant bibliographies by topics / 341.824:338.47 (043.2)

Contents

Journal articles

Academic literature on the topic '341.824:338.47 (043.2)'

Author: Grafiati

Published: 30 May 2022

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic '341.824:338.47 (043.2).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "341.824:338.47 (043.2)"

1

Binkley, Michael S., M. Shahzad Rauf, Sarah A. Milgrom, et al. "Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG." Blood 135, no. 26 (2020): 2365–74. http://dx.doi.org/10.1182/blood.2019003877.

Full text

Abstract:

Abstract Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is an uncommon histologic variant, and the optimal treatment of stage I-II NLPHL is undefined. We conducted a multicenter retrospective study including patients ≥16 years of age with stage I-II NLPHL diagnosed from 1995 through 2018 who underwent all forms of management, including radiotherapy (RT), combined modality therapy (CMT; RT+chemotherapy [CT]), CT, observation after excision, rituximab and RT, and single-agent rituximab. End points were progression-free survival (PFS), freedom from transformation, and overall survival (O

APA, Harvard, Vancouver, ISO, and other styles

2

Marincowitz, Carl, Omar Bouamra, Tim Coates, et al. "1427 The effect of the COVID-19 pandemic on major trauma presentations and patient outcomes in English hospitals." Emergency Medicine Journal 39, no. 12 (2022): A960.2—A964. http://dx.doi.org/10.1136/emermed-2022-rcem2.2.

Full text

Abstract:

Aims, Objectives and BackgroundThere is evidence that COVID-19 ‘lockdowns’ may have contributed to increased non-accidental injury, domestic violence and self-harm related to deteriorating mental health. Internationally, there is also evidence that the diversion of health care resources may led to worse outcomes for patients presenting with major trauma. There has been no previous national evaluation of ‘lockdown’ measures impact on the characteristics, treatment pathways and outcomes of trauma patients in EnglandWe aimed to assess the impact of successive lockdowns on the volume, demographics

APA, Harvard, Vancouver, ISO, and other styles

3

Ritchlin, C. T., P. Rahman, P. Helliwell, et al. "AB0538 POOLED SAFETY RESULTS FROM TWO PHASE-3 TRIALS OF GUSELKUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS THROUGH 1 YEAR." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 1300–1301. http://dx.doi.org/10.1136/annrheumdis-2021-eular.1334.

Full text

Abstract:

Background:DISCOVER 1 & 2, two double-blind, phase-3, psoriatic arthritis (PsA) trials of guselkumab (GUS, an IL-23 inhibitor), demonstrated significant improvement with GUS vs placebo (PBO) in signs and symptoms of PsA, with good tolerability, at week (w) 24 during the PBO-controlled period.1,2 Beyond w24, all patients (pts) switched to GUS. Continued treatment maintained efficacy through w52.3,4Objectives:To describe pooled safety results from the DISCOVER 1 & 2 trials through 1-year of GUS treatment.Methods:Adults with active PsA (DISCOVER 1: ≥3 tender/swollen joints and C-Reactive

APA, Harvard, Vancouver, ISO, and other styles

4

Molina Collada, J., F. Sánchez-Alonso, C. Bohórquez, et al. "OP0138 RISK OF CANCER AFTER BIOLOGIC AND TARGETED SYNTHETIC DMARDS INITIATION IN PATIENTS WITH RHEUMATIC DISEASES AND A HISTORY OF PRIOR MALIGNANCY: DATA FROM THE BIOBADASER REGISTRY." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 88.2–89. http://dx.doi.org/10.1136/annrheumdis-2022-eular.5030.

Full text

Abstract:

BackgroundPatients with a history of cancer are routinely excluded from randomized controlled trials. As consequence, data on the safety of biologic disease modifying antirheumatic drugs (bDMARDS) and targeted synthetic (ts) DMARDs are limited. Although real world data from various national registries have not provided evidence of increased cancer recurrence, additional data from real-world registries may help to confirm safety of non-TNFi bDMARDs and tsDMARDs regarding cancer recurrence to guide treatment decisions.ObjectivesTo compare the risk of incident malignancy with exposure to differen

APA, Harvard, Vancouver, ISO, and other styles

5

Morlà, R., T. LI, G. Luta, and T. Pincus. "AB0786 Self-reported disease burden is greater in spondyloarthritis than in rheumatoid arthritis patients according to multidimensional questionnaire (MDHAQ / RAPID3) scores, despite fewer females, who generally have higher scores on patient questionnaires." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 1520.1–1520. http://dx.doi.org/10.1136/annrheumdis-2022-eular.852.

Full text

Abstract:

BackgroundFemale patients generally have higher scores than males on most items on self-report questionnaires, including MDHAQ/RAPID3 (multi-dimensional health assessment questionnaire/routine assessment of patient index data)1. MDHAQ/RAPID3 was validated in patients with rheumatoid arthritis (RA), but is informative in all diseases studied, including spondyloarthritis (SpA)2. More SpA patients are men than RA patients, suggesting lower scores, but MDHAQ scores are higher in SpA than RA.ObjectivesWe compared self-report MDHAQ/RAPID3 scores in RA vs SpA patients according to gender.MethodsPatie

APA, Harvard, Vancouver, ISO, and other styles

6

Wesseling, Jelle. "Abstract F1-2: Clonal evolution of DCIS to invasion." Cancer Research 83, no. 5_Supplement (2023): F1–2—F1–2. http://dx.doi.org/10.1158/1538-7445.sabcs22-f1-2.

Full text

Abstract:

Abstract Clonal evolution of DCIS to invasion Ductal carcinoma in situ (DCIS) is the most common form of preinvasive breast cancer and, despite treatment, a small fraction (5-10%) of DCIS patients develop subsequent invasive breast cancer (IBC). If not treated, at least 3 out of 4 women with DCIS will not develop IBC1-3. This implies many women with non-progressive, low-risk DCIS are likely to carry the burden of overtreatment. To solve this DCIS dilemma, two fundamental questions need to be answered. The first question is, how the subsequent IBC is related to the initial DCIS lesion. The seco

APA, Harvard, Vancouver, ISO, and other styles

7

sprotocols. "A rapid one-step kinetics-based immunoassay procedure for the highly-sensitive detection of C-reactive protein." December 31, 2014. https://doi.org/10.5281/zenodo.13656.

Full text

Abstract:

Authors: Sandeep Kumar Vashist, Gregor Czilwik, Thomas van Oordt, Felix von Stetten, Roland Zengerle, E. Marion Schneider & John H.T. Luong ### Abstract A rapid one-step kinetics-based sandwich enzyme-linked immunosorbent (ELISA) procedure has been developed for highly-sensitive detection of C-reactive protein (CRP) in less than 30 min. With minimal process steps, the procedure is highly simplified and cost-effective. The analysis only involves sequentially the formation of a sandwich immune complex on capture anti-CRP antibody (Ab)-bound Dynabeads, followed by two magnet-assisted washings

APA, Harvard, Vancouver, ISO, and other styles

8

sprotocols. "Integration of screening and identifying ligand(s) from medicinal plant extracts based on target recognition by using NMR spectroscopy." January 3, 2015. https://doi.org/10.5281/zenodo.13696.

Full text

Abstract:

Authors: Yalin Tang, Qian Shang, Junfeng Xiang, Qianfan Yang, Qiuju Zhou, Lin Li, Hong Zhang, Qian Li, Hongxia Sun, Aijiao Guan, Wei Jiang & Wei Gai ### Abstract This protocol presents the screening of ligand(s) from medicinal plant extracts based on target recognition by using NMR spectroscopy. A detailed description of sample preparation and analysis process is provided. NMR spectroscopies described here are 1H NMR, diffusion-ordered spectroscopy (DOSY), relaxation-edited NMR, 1H–13C HSQC and HMBC. This method includes three steps: First, investigate the NMR spectroscopy properties of ta

APA, Harvard, Vancouver, ISO, and other styles

9

Dolomatov, S.I., та W. Zukow. "Эпигенетика почек = Kidneys epigenetics". 7 липня 2019. https://doi.org/10.5281/zenodo.3270754.

Full text

Abstract:

<strong>Dolomatov S.I., Zukow W. </strong><strong>Эпигенетика почек</strong><strong> = Kidney</strong><strong>s</strong><strong> epigenetics</strong><strong>. </strong><strong>RSW. Radom,</strong><strong> 144 </strong><strong>p. ISBN </strong><strong>9780359774524</strong><strong>.</strong><strong> DOI </strong><strong>http://dx.doi.org/10.5281/zenodo.3270699</strong><strong> PBN Poland </strong><strong>https://pbn.nauka.gov.pl/sedno-webapp/works/917606</strong>           <strong>Radomska Szkoła Wyższa w Radomiu, Radom, Poland</strong>         &nbsp

APA, Harvard, Vancouver, ISO, and other styles

10

Ameku, W.A., V.N. Ataide, E.T. Costab, et al. "A pencil-lead immunosensor for the rapid electrochemical measurement of anti-Diphtheria Toxin antibodies." October 30, 2021. https://doi.org/10.5281/zenodo.5628477.

Full text

Abstract:

<strong>Abstract: </strong>Diphtheria is a vaccine-preventable disease, yet immunization can wane over time to non-protective levels. We have developed a low-cost, miniaturized electroanalytical biosensor to quantify anti-diphtheria toxin (DTx) immunoglobulin G (IgG) antibody to minimize the risk for localized outbreaks. Two epitopes specific to DTx and recognized by antibodies generated post-vaccination were selected to create a bi-epitope peptide, biEP, by synthesizing the epitopes in tandem. The biEP peptide was conjugated to the surface of a pencil-lead electrode (PLE) integrated into a po

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!